Denali TherapeuticsDNLI
About: Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Employees: 390
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
72% more call options, than puts
Call options by funds: $2.01M | Put options by funds: $1.17M
58% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 24
33% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 58
31% more capital invested
Capital invested by funds: $2.81B [Q2] → $3.67B (+$868M) [Q3]
7% more funds holding
Funds holding: 200 [Q2] → 214 (+14) [Q3]
3.38% more ownership
Funds ownership: 84.72% [Q2] → 88.1% (+3.38%) [Q3]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q2] → 1 (-1) [Q3]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
HC Wainwright & Co. Andrew Fein 50% 1-year accuracy 101 / 202 met price target | 259%upside $90 | Buy Reiterated | 7 Nov 2024 |
Jefferies Michael Yee 40% 1-year accuracy 4 / 10 met price target | 80%upside $45 | Buy Maintained | 1 Nov 2024 |
JP Morgan Jessica Fye 63% 1-year accuracy 30 / 48 met price target | 12%upside $28 | Overweight Maintained | 11 Oct 2024 |
Cantor Fitzgerald Charles Duncan 65% 1-year accuracy 54 / 83 met price target | 40%upside $35 | Overweight Reiterated | 9 Sept 2024 |
HC Wainwright & Co. Andrew Fein 50% 1-year accuracy 101 / 202 met price target | 259%upside $90 | Buy Reiterated | 4 Sept 2024 |
Financial journalist opinion
Based on 4 articles about DNLI published over the past 30 days
